Correct. Historically the FDA have always put efficacy above safety. Efficacy with some side effects trumps no side effects with limited efficacy. So with that argument in mind the deciding question put to ODAC is the one the FDA wanted a definitive answer for - Does it work?
FDA does not over-rule positive ODAC decisions, page-11
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.48 |
Change
0.105(7.64%) |
Mkt cap ! $1.689B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.49 | $1.38 | $8.181M | 5.685M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 25443 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.48 | 60811 | 4 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |